Want to see DNLI full AI Analyst Report?
DNLI Stock Chart & Stats
$20.57
$0.28(1.32%)
At close: 4:00 PM EST
$20.57
$0.28(1.32%)
Day’s Range― - ―
52-Week Range$12.58 - $27.30
Previous CloseN/A
Volume399.31K
Average Volume (3M)1.98M
Market Cap
$3.61B
Enterprise Value$3.38B
Total Cash (Recent Filing)$987.68M
Total Debt (Recent Filing)$40.05M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Jul 30, 2026EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.88
Shares Outstanding158,709,730
10 Day Avg. Volume1,812,747
30 Day Avg. Volume1,981,055
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)2.86
Price to Sales (P/S)0.00
P/FCF Ratio-6.86
Enterprise Value/Market Cap0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-591.93
Enterprise Value/Ebitda-6.85
Forecast
1Y Price Target
$34.20Price Target Upside66.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.46
Revenue Forecast (FY)$42.96M
Bulls Say, Bears Say
Bulls Say
Proprietary BBB TransportVehicle PlatformDenali’s TransportVehicle platform is a structural competitive advantage: enabling blood–brain barrier delivery addresses a persistent biomedical bottleneck, supports multiple indications (neurodegenerative and lysosomal), attracts partners, and creates scalable R&D optionality that remains relevant over months as programs advance.
Low Leverage And Sizable Equity BufferA low debt load and substantial equity provide durable solvency resilience and financial flexibility: this reduces bankruptcy risk, supports continued clinical spending, and improves the company’s ability to pursue partnerships or monetizations without immediate distress-driven decisions.
Non-dilutive $195M PRV Monetization Bolstering RunwaySelling the FDA priority review voucher generates sizable non-dilutive cash that materially extends the company’s runway, funds TransportVehicle-enabled clinical and IND programs, and reduces short-term financing pressure—supporting sustained R&D execution and strategic optionality over coming quarters.
Bears Say
Large Negative Cash Flow And High BurnPersistently negative operating and free cash flow at roughly half a billion annualized implies ongoing funding needs; absent durable revenue, the company must repeatedly access markets, partners, or sell assets, increasing dilution risk and constraining sustained multi-program development without new cash sources.
Major Phase 2b Parkinson’s Trial FailureThe LUMA failure materially narrows near-term pipeline and removes a partnered development path, raising program-level risk and reducing potential milestone/revenue opportunities. It increases reliance on fewer programs and heightens the importance of upcoming trial readouts to restore program momentum.
No Recurring Revenue; Revenue Dropped To $0Loss of recurring revenue undermines predictability of cash inflows and forces dependence on milestone payments, asset sales, or financing. This structural revenue instability complicates long-term planning, elevates financing frequency and cost, and increases execution risk for multi-year clinical programs.
Denali Therapeutics News
DNLI FAQ
What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was $12.58 and its highest was $27.30 in the past 12 months.
What is Denali Therapeutics’s market cap?
Denali Therapeutics’s market cap is $3.61B.
When is Denali Therapeutics’s upcoming earnings report date?
Denali Therapeutics’s upcoming earnings report date is Jul 30, 2026 which is in 12 days.
How were Denali Therapeutics’s earnings last quarter?
Denali Therapeutics released its earnings results on May 07, 2026. The company reported -$0.69 earnings per share for the quarter, beating the consensus estimate of -$0.723 by $0.033.
Is Denali Therapeutics overvalued?
According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued.
Does Denali Therapeutics pay dividends?
Denali Therapeutics does not currently pay dividends.
What is Denali Therapeutics’s EPS estimate?
Denali Therapeutics’s EPS estimate is -0.71.
How many shares outstanding does Denali Therapeutics have?
Denali Therapeutics has 158,709,730 shares outstanding.
What happened to Denali Therapeutics’s price movement after its last earnings report?
Denali Therapeutics reported an EPS of -$0.69 in its last earnings report, beating expectations of -$0.723. Following the earnings report the stock price went down -0.457%.
Which hedge fund is a major shareholder of Denali Therapeutics?
Currently, no hedge funds are holding shares in DNLI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Denali Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.20 (66.26% Upside)
$34.20 (66.26% Upside)
Blogger Sentiment
Bullish
DNLI Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 27.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.85%
12-Months-Change
Fundamentals
Return on Equity
-52.20%
Trailing 12-Months
Asset Growth
-0.42%
Trailing 12-Months
Company Description
Denali Therapeutics
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
DNLI Stock 12 Month Forecast
Average Price Target
$34.20
▲(66.26% Upside)
Technical Analysis
Agios Pharma
―
Celcuity
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Ownership Overview
5.34% Insiders
24.13% Mutual Funds
0.17% Other Institutional Investors
52.53% Public Companies and
Individual Investors